The Assessment of the risk/benefit ratio of phase II cancer clincal trials by Institutional Review Board (IRB) members

H.E.M. van Luijn, R.B. Keus, W.M. Robinson, N.K. Aaronson

Research output: Contribution to JournalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'The Assessment of the risk/benefit ratio of phase II cancer clincal trials by Institutional Review Board (IRB) members'. Together they form a unique fingerprint.

Medicine & Life Sciences